OIS@ASRS
Aron Shapiro, vice president at Ora Inc., gives a comprehensive overview of the challenges and opportunities of retina therapies. Shapiro discusses Ora’s early work with…
Read More
Pars plana vitrectomy is almost a half-century old, and the earliest probes were powered by batteries, said Cynthia A. Toth, MD, the Joseph A.C. Wadsworth…
Read More
Cedric Francois, CEO, Apellis Pharmaceuticals, hopes to deliver positive results to the company’s Phase II clinical trials of APL-2, a peptide targeting the C3 inhibitor…
Read More
Jeffrey Cleland, president and CEO, Graybug Vision, delivered an update on its two treatments for wet age-related macular degeneration (Wet AMD) and glaucoma. The company…
Read More
Edwin Madison, PhD, chief scientific officer, Catalyst Biosciences, says the company is developing protease therapeutic agents that work via a catalytic rather than a stoichiometric…
Read More
Shelley Boyd, MD, president and CSO, Translatum Medicus Inc. (TMi), reports the company has started raising capital to initiate preclinical studies – and possibly Phase…
Read More
If cost was no consideration, retina specialists would first chose Eylea for their own anti-VEGF therapy, according to an American Society of Retina Specialists survey,…
Read More
Alimera Sciences is focused on the commercialization of ILUVIEN (fluocinolone acetonide intravitreal implant) for diabetic macular edema (DME), which received FDA approval in 2014. The…
Read More
Most ophthalmologists are aware that Aerie Pharmaceuticals is developing Rho-kinase and norepinephrine transporter inhibitors (Rhopressa, or netarsudil) for the treatment of glaucoma, and that the…
Read More
Ocular Therapeutix has built a portfolio of products around its proprietary hydrogel technology. ReSure Sealant is FDA approved for sealing clear corneal incisions following cataract…
Read More
Intrasurgical optical coherence tomography (OCT) is “going to make a dramatic impact on our patients’ lives,” said Eric Buckland, founder and CEO of Bioptigen, which…
Read More
TrueVision Systems’ 3D Digital Microscope Platform recently received a boost thanks to a partnership agreement with Alcon penned just before OIS@ASRS, TrueVision CEO Forrest Fleming…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")